Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors

NCT04332653 is registered in ClinicalTrials.gov with NeoImmuneTech as lead sponsor.

NCT NCT04332653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04332653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors
Lead sponsor
NeoImmuneTech
Phase
Phase 1/2
Overall status
Completed
Start date
June 10, 2020
Completion date
January 13, 2025
Enrollment
215 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

any advanced solid tumors, microsatellite stable colorectal cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer, small cell lung cancer, triple negative breast cancer